Passage Bio and Remix Therapeutics Agree to Merge Into One Firm
Passage Bio and Remix Therapeutics have signed a merger deal, with the combined company set to operate under the Remix Therapeutics name.
Passage Bio and Remix Therapeutics announced a definitive merger agreement that will consolidate the two biotech firms under a single corporate banner, the companies disclosed via GlobalNewswire. The surviving entity will carry the Remix Therapeutics name, signaling where the combined organization's strategic priorities will lie.
The merged company intends to advance Remix's existing pipeline of small molecule therapies, a class of drugs that work by reprogramming RNA processing rather than targeting proteins downstream of a disease. That approach is designed to intervene at the origin of disease drivers, potentially offering more fundamental corrections than conventional therapeutic strategies.
Read more UK Tribunal Clears $4B Apple iCloud Class Action Suit →
RNA-targeting small molecules represent a growing frontier in drug discovery, as scientists seek to influence gene expression and splicing before faulty proteins are ever produced. By folding Passage Bio's resources and structure into Remix's scientific platform, the combined company positions itself to accelerate development of that pipeline with what could be a broader capital and operational base.
The announcement does not detail the financial terms of the merger or specify how existing shareholders of each company will be treated in the transaction. As the deal moves toward closing, investors and industry observers will be watching to see how management teams are integrated and which programs are prioritized within the newly unified pipeline.
Continue reading at GlobalNewswire.
